Showing results (171-180 of 183) with videos related to
Sort By:
Pageof 19
Journal of Acquired Immune Deficiency Syndromes (1999)|April 29, 2009
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppressionEsteban Martínez, José A Arranz, Daniel Podzamczer, et al.The Journal of Antimicrobial Chemotherapy|September 19, 2023
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimensDaniel Podzamczer, Arkaitz Imaz, Ana Lopez-Lirola, et al.The Lancet. Infectious Diseases|February 15, 2014
Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trialRichard B Pollard, Jürgen K Rockstroh, Giuseppe Pantaleo, et al.Enfermedades Infecciosas Y Microbiologia Clinica|February 26, 2017
Executive summary: Pre-exposure prophylaxis for prevention of HIV infection in adults in Spain: July 2016Santiago Moreno, Antonio Antela, Felipe García, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2011
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe, , Fumiyo Nakagawa, et al.The Journal of Infectious Diseases|December 11, 2012
Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes, Dominique Costagliola, Bruno Ledergerber, et al.Enfermedades Infecciosas Y Microbiologia Clinica|July 3, 2014
Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014), Juan Berenguer, Rosa Polo, et al.Enfermedades Infecciosas Y Microbiologia Clinica|May 30, 2015
Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015), Juan Berenguer, Rosa Polo, et al.Medicine|February 13, 2016
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled TrialWarren Dinges, Pierre-Marie Girard, Daniel Podzamczer, et al.Archives of Internal Medicine|March 10, 2010
Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years, Rebecca Lodwick, Dominique Costagliola, et al.Pageof 19